Open-label study of the short-term effects of memantine on FDG-PET in frontotemporal dementia

Tiffany W Chow1&ndash;6, Ariel Graff-Guerrero4,6, Nicolaas PLG Verhoeff2&ndash;4,7, Malcolm A Binns3,8, David F Tang-Wai5,9, Morris Freedman1,3,5, Mario Masellis5,10, Sandra E Black3,5,10, Alan A Wilson4,6, Sylvain Houle4,6, Bruce G Pollock4,61Division of Neurology, 2Department of Ps...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Chow TW, Graff-Guerrero A, Verhoeff NP, Binns MA, Tang-Wai DF, Freedman M, Masellis M, Black SE, Wilson AA, Houle S, Pollock BG
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2011
Materias:	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
Acceso en línea:	https://doaj.org/article/8907b36c3b844e2b984d0c77c9064601
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:8907b36c3b844e2b984d0c77c9064601
record_format	dspace
spelling	oai:doaj.org-article:8907b36c3b844e2b984d0c77c90646012021-12-02T08:26:13ZOpen-label study of the short-term effects of memantine on FDG-PET in frontotemporal dementia1176-63281178-2021https://doaj.org/article/8907b36c3b844e2b984d0c77c90646012011-07-01T00:00:00Zhttp://www.dovepress.com/open-label-study-of-the-short-term-effects-of-memantine-on-fdg-pet-in--a7870https://doaj.org/toc/1176-6328https://doaj.org/toc/1178-2021Tiffany W Chow1&ndash;6, Ariel Graff-Guerrero4,6, Nicolaas PLG Verhoeff2&ndash;4,7, Malcolm A Binns3,8, David F Tang-Wai5,9, Morris Freedman1,3,5, Mario Masellis5,10, Sandra E Black3,5,10, Alan A Wilson4,6, Sylvain Houle4,6, Bruce G Pollock4,61Division of Neurology, 2Department of Psychiatry, 3Rotman Research Institute, Baycrest; 4Departments of Psychiatry, 5Medicine, Division of Neurology, University of Toronto; 6Centre for Addiction and Mental Health PET Centre; 7Kunin-Lunenfeld Applied Research Unit, Baycrest; 8Dalla Lana School of Public Health, University of Toronto; 9University Health Network Memory Clinic; 10LC Campbell Cognitive Neurology Research Unit, Department of Medicine (Neurology), Sunnybrook Health Sciences Centre, Toronto, ON, CanadaBackground: Memantine has shown effects on cortical metabolism in Alzheimer&#39;s disease (AD), and the mechanism of action may not be specific to AD alone. We hypothesized that participants with frontotemporal dementia taking memantine would show an increased cortical metabolic activity in frontal regions, temporal regions, or in salience network hubs.Methods: Sixteen participants with behavioral or language variant frontotemporal dementia syndromes (FTD) were recruited from tertiary FTD clinics and treated with memantine hydrochloride 10 mg twice daily in this fixed-dose, open-label pilot study. The primary endpoint was enhancement of cortical metabolic activity after 7&ndash;8 weeks of treatment. Secondary endpoints were measures of mood and behavior disturbance, frontal executive function, and motor disturbance.Results: Voxel-wise parametric image analysis of positron emission tomography (PET) data from seven behavioral variant FTD patients, eight semantic dementia patients, and one progressive nonfluent aphasia patient, of mean age 64.3 years, mean duration of illness 4.25 years, and baseline mean sum of boxes Clinical Dementia Rating score 6.59, revealed an increase in [18F]-fluorodeoxyglucose (FDG) normalized metabolic activity in bilateral insulae and the left orbitofrontal cortex (P &lt; 0.01). The increase on FDG-PET did not correlate with changes on behavioral inventories. Post hoc analysis indicated that semantic dementia participants drove this finding.Conclusion: This open-label clinical PET study suggests that memantine induces an increase in metabolism in the salience network in FTD. A placebo-controlled follow-up study is warranted.Keywords: Alzheimer&#39;s disease, frontotemporal dementia, metabolism, PET scan, semantic dementia&nbsp;Chow TWGraff-Guerrero AVerhoeff NPBinns MATang-Wai DFFreedman MMasellis MBlack SEWilson AAHoule SPollock BGDove Medical PressarticleNeurosciences. Biological psychiatry. NeuropsychiatryRC321-571Neurology. Diseases of the nervous systemRC346-429ENNeuropsychiatric Disease and Treatment, Vol 2011, Iss Issue 1, Pp 415-424 (2011)
institution	DOAJ
collection	DOAJ
language	EN
topic	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
spellingShingle	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429 Chow TW Graff-Guerrero A Verhoeff NP Binns MA Tang-Wai DF Freedman M Masellis M Black SE Wilson AA Houle S Pollock BG Open-label study of the short-term effects of memantine on FDG-PET in frontotemporal dementia
description	Tiffany W Chow1&ndash;6, Ariel Graff-Guerrero4,6, Nicolaas PLG Verhoeff2&ndash;4,7, Malcolm A Binns3,8, David F Tang-Wai5,9, Morris Freedman1,3,5, Mario Masellis5,10, Sandra E Black3,5,10, Alan A Wilson4,6, Sylvain Houle4,6, Bruce G Pollock4,61Division of Neurology, 2Department of Psychiatry, 3Rotman Research Institute, Baycrest; 4Departments of Psychiatry, 5Medicine, Division of Neurology, University of Toronto; 6Centre for Addiction and Mental Health PET Centre; 7Kunin-Lunenfeld Applied Research Unit, Baycrest; 8Dalla Lana School of Public Health, University of Toronto; 9University Health Network Memory Clinic; 10LC Campbell Cognitive Neurology Research Unit, Department of Medicine (Neurology), Sunnybrook Health Sciences Centre, Toronto, ON, CanadaBackground: Memantine has shown effects on cortical metabolism in Alzheimer&#39;s disease (AD), and the mechanism of action may not be specific to AD alone. We hypothesized that participants with frontotemporal dementia taking memantine would show an increased cortical metabolic activity in frontal regions, temporal regions, or in salience network hubs.Methods: Sixteen participants with behavioral or language variant frontotemporal dementia syndromes (FTD) were recruited from tertiary FTD clinics and treated with memantine hydrochloride 10 mg twice daily in this fixed-dose, open-label pilot study. The primary endpoint was enhancement of cortical metabolic activity after 7&ndash;8 weeks of treatment. Secondary endpoints were measures of mood and behavior disturbance, frontal executive function, and motor disturbance.Results: Voxel-wise parametric image analysis of positron emission tomography (PET) data from seven behavioral variant FTD patients, eight semantic dementia patients, and one progressive nonfluent aphasia patient, of mean age 64.3 years, mean duration of illness 4.25 years, and baseline mean sum of boxes Clinical Dementia Rating score 6.59, revealed an increase in [18F]-fluorodeoxyglucose (FDG) normalized metabolic activity in bilateral insulae and the left orbitofrontal cortex (P &lt; 0.01). The increase on FDG-PET did not correlate with changes on behavioral inventories. Post hoc analysis indicated that semantic dementia participants drove this finding.Conclusion: This open-label clinical PET study suggests that memantine induces an increase in metabolism in the salience network in FTD. A placebo-controlled follow-up study is warranted.Keywords: Alzheimer&#39;s disease, frontotemporal dementia, metabolism, PET scan, semantic dementia&nbsp;
format	article
author	Chow TW Graff-Guerrero A Verhoeff NP Binns MA Tang-Wai DF Freedman M Masellis M Black SE Wilson AA Houle S Pollock BG
author_facet	Chow TW Graff-Guerrero A Verhoeff NP Binns MA Tang-Wai DF Freedman M Masellis M Black SE Wilson AA Houle S Pollock BG
author_sort	Chow TW
title	Open-label study of the short-term effects of memantine on FDG-PET in frontotemporal dementia
title_short	Open-label study of the short-term effects of memantine on FDG-PET in frontotemporal dementia
title_full	Open-label study of the short-term effects of memantine on FDG-PET in frontotemporal dementia
title_fullStr	Open-label study of the short-term effects of memantine on FDG-PET in frontotemporal dementia
title_full_unstemmed	Open-label study of the short-term effects of memantine on FDG-PET in frontotemporal dementia
title_sort	open-label study of the short-term effects of memantine on fdg-pet in frontotemporal dementia
publisher	Dove Medical Press
publishDate	2011
url	https://doaj.org/article/8907b36c3b844e2b984d0c77c9064601
work_keys_str_mv	AT chowtw openlabelstudyoftheshorttermeffectsofmemantineonfdgpetinfrontotemporaldementia AT graffguerreroa openlabelstudyoftheshorttermeffectsofmemantineonfdgpetinfrontotemporaldementia AT verhoeffnp openlabelstudyoftheshorttermeffectsofmemantineonfdgpetinfrontotemporaldementia AT binnsma openlabelstudyoftheshorttermeffectsofmemantineonfdgpetinfrontotemporaldementia AT tangwaidf openlabelstudyoftheshorttermeffectsofmemantineonfdgpetinfrontotemporaldementia AT freedmanm openlabelstudyoftheshorttermeffectsofmemantineonfdgpetinfrontotemporaldementia AT masellism openlabelstudyoftheshorttermeffectsofmemantineonfdgpetinfrontotemporaldementia AT blackse openlabelstudyoftheshorttermeffectsofmemantineonfdgpetinfrontotemporaldementia AT wilsonaa openlabelstudyoftheshorttermeffectsofmemantineonfdgpetinfrontotemporaldementia AT houles openlabelstudyoftheshorttermeffectsofmemantineonfdgpetinfrontotemporaldementia AT pollockbg openlabelstudyoftheshorttermeffectsofmemantineonfdgpetinfrontotemporaldementia
_version_	1718398498321203200

Open-label study of the short-term effects of memantine on FDG-PET in frontotemporal dementia

Ejemplares similares